CSBR Champions Oncology, Inc.
USHealthcareAs of 2026-07-10 16:00
Why CSBR matters now
Champions Oncology, Inc. (CSBR) is a US stock in Healthcare. The latest InvestLog snapshot shows $5.82 with +0.17% on the session and $80.8M in market capitalization; recent performance reads 1-month +5.69% and YTD -8.54%.
The latest financial table shown here is Q3 2026, with revenue of $16.6M, net income of $-279.0K, and EPS of $-0.02. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield 4.3%.
The latest indexable market news headline is "Champions Oncology (NASDAQ:CSBR) Share Price Passes Below Two Hundred Day Moving Average – Time to Sell?" from Defense World.
Additional event context on this page matters because analyst consensus is Buy with a median target of $12.00; recent insider activity includes Brainin Robert Lawrence filing A-Award. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
20.49
P/S
1.51
EV/EBITDA
-90.33
DCF Value
$9.73
FCF Yield
4.3%
Div Yield
0.0%
Margins & Returns
Gross Margin
45.9%
Operating Margin
-3.8%
Net Margin
-3.9%
ROE
-58.0%
ROA
-8.0%
ROIC
-23.2%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2026 | $16.6M | $-279.0K | $-0.02 |
| Q2 2026 | $15.0M | $299.0K | $0.02 |
| Q1 2026 | $14.0M | $-466.0K | $-0.03 |
| Q4 2025 | $12.4M | $-1.8M | $-0.13 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$12.00
Target (Median)
$12.00
Target Range
$12.00 - $12.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
0.40
Champions Oncology, Inc. is dedicated to developing and commercializing cutting-edge technological products and services designed to personalize cancer treatment and streamline the development of oncology drugs across the United States. At the heart of its offerings is the Tumorgraft Technology Platform, an innovative approach that facilitates individualized cancer care by implanting human tumors into immune-deficient mice. Utilizing this proprietary platform, the company not only delivers personalized cancer solutions directly but also provides Translational Oncology Solutions, supporting pharmaceutical and biotechnology companies through their drug development lifecycle. Additionally, Champions Oncology offers Lumin Bioinformatics, a comprehensive software platform and data tool filled with insights from research services and clinical studies, accessible through annual subscriptions. The company distributes its offerings through various channels, including online platforms, word-of-mouth referrals, and a dedicated sales team, reaching both patients and healthcare professionals. Established in 1985, Champions Oncology, Inc. is based in Hackensack, New Jersey, and was formerly known as Champions Biotechnology, Inc. until its name change in April 2011.